1
|
Jarkovská D, Miklovič M, Švíglerová J, Červenka L, Škaroupková P, Melenovský V, Štengl M. Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure. Front Pharmacol 2021; 12:729568. [PMID: 34566652 PMCID: PMC8460913 DOI: 10.3389/fphar.2021.729568] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 08/31/2021] [Indexed: 11/16/2022] Open
Abstract
Chronic volume overload induces multiple cardiac remodeling processes that finally result in eccentric cardiac hypertrophy and heart failure. We have hypothesized that chronic angiotensin-converting enzyme (ACE) inhibition by trandolapril might affect various remodeling processes differentially, thus allowing their dissociation. Cardiac remodeling due to chronic volume overload and the effects of trandolapril were investigated in rats with an aortocaval fistula (ACF rats). The aortocaval shunt was created using a needle technique and progression of cardiac remodeling to heart failure was followed for 24 weeks. In ACF rats, pronounced eccentric cardiac hypertrophy and contractile and proarrhythmic electrical remodeling were associated with increased mortality. Trandolapril substantially reduced the electrical proarrhythmic remodeling and mortality, whereas the effect on cardiac hypertrophy was less pronounced and significant eccentric hypertrophy was preserved. Effective suppression of electrical proarrhythmic remodeling and mortality but not hypertrophy indicates that the beneficial therapeutic effects of ACE inhibitor trandolapril in volume overload heart failure might be dissociated from pure antihypertrophic effects.
Collapse
Affiliation(s)
- Dagmar Jarkovská
- Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia.,Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
| | - Matúš Miklovič
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.,Department of Pathophysiology, 2 Faculty of Medicine, Charles University, Prague, Czechia
| | - Jitka Švíglerová
- Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia.,Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
| | - Luděk Červenka
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.,Department of Pathophysiology, 2 Faculty of Medicine, Charles University, Prague, Czechia
| | - Petra Škaroupková
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia
| | - Vojtěch Melenovský
- Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia
| | - Milan Štengl
- Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia.,Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
| |
Collapse
|
2
|
Gomes C, Ferreira D, Carvalho JPF, Barreto CAV, Fernandes J, Gouveia M, Ribeiro F, Duque AS, Vieira SI. Current genetic engineering strategies for the production of antihypertensive ACEI peptides. Biotechnol Bioeng 2020; 117:2610-2628. [PMID: 32369185 DOI: 10.1002/bit.27373] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 04/16/2020] [Accepted: 05/02/2020] [Indexed: 12/16/2022]
Abstract
Hypertension is a major and highly prevalent risk factor for various diseases. Among the most frequently prescribed antihypertensive first-line drugs are synthetic angiotensin I-converting enzyme inhibitors (ACEI). However, since their use in hypertension therapy has been linked to various side effects, interest in the application of food-derived ACEI peptides (ACEIp) as antihypertensive agents is rapidly growing. Although promising, the industrial production of ACEIp through conventional methods such as chemical synthesis or enzymatic hydrolysis of food proteins has been proven troublesome. We here provide an overview of current antihypertensive therapeutics, focusing on ACEI, and illustrate how biotechnology and bioengineering can overcome the limitations of ACEIp large-scale production. Latest advances in ACEIp research and current genetic engineering-based strategies for heterologous production of ACEIp (and precursors) are also presented. Cloning approaches include tandem repeats of single ACEIp, ACEIp fusion to proteins/polypeptides, joining multivariate ACEIp into bioactive polypeptides, and producing ACEIp-containing modified plant storage proteins. Although bacteria have been privileged ACEIp heterologous hosts, particularly when testing for new genetic engineering strategies, plants and microalgae-based platforms are now emerging. Besides being generally safer, cost-effective and scalable, these "pharming" platforms can perform therelevant posttranslational modifications and produce (and eventually deliver) biologically active protein/peptide-based antihypertensive medicines.
Collapse
Affiliation(s)
- Carolina Gomes
- Department of Integrative Plant Biology, Institute of Plant Genetics, Polish Academy of Sciences, Poznań, Poland.,Plant Cell Biotechnology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Green-it Unit, Oeiras, Portugal
| | - Diana Ferreira
- Department of Medical Sciences (DCM), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| | - João P F Carvalho
- Department of Medical Sciences (DCM), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| | - Carlos A V Barreto
- Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.,Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Coimbra, Portugal
| | - Joana Fernandes
- Department of Medical Sciences (DCM), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| | - Marisol Gouveia
- Department of Medical Sciences (DCM), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| | - Fernando Ribeiro
- School of Health Sciences (ESSUA), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| | - Ana S Duque
- Plant Cell Biotechnology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Green-it Unit, Oeiras, Portugal
| | - Sandra I Vieira
- Department of Medical Sciences (DCM), Institute of Biomedicine (iBiMED), Universidade de Aveiro, Aveiro, Portugal
| |
Collapse
|